eMedicine Specialties > Rheumatology > Metabolic and Bone Disease
Avascular Necrosis
Updated: Dec 17, 2009
Introduction
Background
Avascular necrosis (AVN) is defined as cellular death of bone components due to interruption of the blood supply; the bone structures then collapse, resulting in bone destruction, pain, and loss of joint function. AVN is associated with numerous conditions and usually involves the epiphysis of long bones, such as the femoral and humeral heads and the femoral condyles, but small bones can also be affected. In clinical practice, AVN is most commonly encountered in the hip. Recently, AVN of the jaw associated with bisphosphonate use has also been described.1
Early diagnosis and appropriate intervention can delay the need for joint replacement. However, most patients present late in the disease course. Without treatment, the process is almost always progressive, leading to joint destruction within 5 years. Patients taking corticosteroids and organ transplant recipients are particularly at risk of developing AVN. Most available data regarding the natural history, pathology, pathogenesis, and treatment of AVN pertains to femoral head necrosis.
Pathophysiology
Although the pathophysiology of AVN is not fully understood, the final common pathway is interruption of blood flow to the bone. AVN affects bones with a single terminal blood supply, such as the femoral head, carpals, talus, and humerus. These bones have limited collateral circulation. Interruption of the vascular supply and resultant necrosis of marrow, medullary bone, and cortex are theorized to be caused by the mechanisms listed below. However, individual patients usually have more than one risk factor; this indicates that the pathogenesis of AVN is likely multifactorial.
- Vascular occlusion: This is characterized by the interruption of the extraosseous blood supply via factors such as direct trauma (eg, fracture, dislocation), nontraumatic stress, and stress fracture.
- Altered lipid metabolism: Animal studies have led to the hypothesis that increased levels of serum lipids leads to lipid deposition in the femoral head, causing femoral hypertension and ischemia.2 Lipid-level–lowering drugs in animals reverse this process. Corticosteroid administration was associated with fat emboli in the femoral heads of rabbits.3
- Intravascular coagulation: Disorders of the coagulation system have been implicated in the pathogenesis of AVN. Typically, it is a secondary event triggered by a familial thrombophilia, hypercholesterolemia, allograft organ rejection, other disorders (eg, infection, malignancy), or pregnancy.
- Healing process: Necrotic bone triggers a process of repair that includes osteoclasts, osteoblasts, histiocytes, and vascular elements. Osteoblasts build new bone on top of the dead bone, leading to a thick scar that prevents revascularization of the necrotic bone, with resultant abnormal joint remodeling and joint dysfunction.
- Primary cell death: Osteocyte death without other features of AVN has been seen in renal transplant patients, as well as in patients receiving steroids and those who consume significant amounts of alcohol.
- Mechanical stress: Animal studies have shown an association between increased weight bearing and an increased incidence of AVN of the femoral head.
Frequency
United States
The frequency of AVN depends on the site involved. The most common site is the hip; other locations include the carpals, talus, femur, metatarsal, mandible, and humerus. In the United States, approximately 15,000 new cases of AVN are reported each year. AVN accounts for more than 10% of total hip replacement surgeries performed in the United States. Most recently, 380 cases of osteonecrosis of the jaw associated with bisphosphonate use have been reported. Most patients with osteonecrosis of the jaw also had an ongoing malignancy and/or had undergone a recent dental procedure.4,1
International
In most countries, the incidence and prevalence of AVN are unknown. A Japanese survey estimated that 2500-3300 cases of AVN of the hip occur each year; of these, 34.7% were due to corticosteroid use, 21.8% to alcohol abuse, and 37.1% to idiopathic mechanisms.5 A study from France reported AVN in 4.3% of allogenic bone marrow transplant recipients.6
Mortality/Morbidity
Data on mortality rates associated with AVN are not available. Most data involve AVN of the hip. Mortality rates are very low and vary based on the operative procedure used to treat AVN.
Morbidity rates are high and depend on the underlying cause. Morbidity rates associated with AVN of the hip are high; the prevalence of long-term disability is significant. Despite advances in orthopedic procedures, most patients with advanced AVN require more than one hemiarthroplasty or total hip replacement during their lifetime.
Race
AVN has no racial predilection except for cases associated with sickle cell disease and hemoglobin S and SC disease, which predominantly occur in people of African and Mediterranean descent.
Sex
With the exception of AVN associated with systemic lupus erythematosus, AVN is more common in men, with an overall male-to-female ratio of 8:1.
Age
AVN is a disease of middle age that most often occurs during the fourth or fifth decade of life and is bilateral in 55% of cases.
Clinical
History
- Avascular necrosis (AVN) may be asymptomatic and is occasionally discovered incidentally on radiographs. Symptoms depend on the affected joint. Medullary infarcts are usually silent, and infarcts of the small bones of the hands and feet are often symptomatic.
- Pain in the affected joint is typically the presenting symptom of AVN, regardless of the location. Patients with AVN of the femoral head often report groin pain that is exacerbated by weight bearing. The pain may initially be mild but progressively worsens over time and with use. Eventually, the pain is present at rest and may be present at night.
- Large infarcts, such as those due to Gaucher disease and hemoglobinopathies, are associated with very severe pain.
Physical
- Initially, the physical examination findings of AVN may be unrevealing. Abnormal physical findings depend on the location and severity of disease. With progression of AVN of the hip, joint function deteriorates and the patient may walk with a limp. AVN of smaller, non–weight-bearing joints typically does not cause significant disability.
- Patients with AVN may have tenderness around the affected bone.
- Both active and passive joint movements may be restricted and painful.
- A neurologic deficit may be present if a nerve is affected (compressed) because of necrosis and compression deformity of affected bones.
- Advanced AVN can cause joint deformity and muscle wasting.
Causes
AVN is associated with several clinical conditions. The following etiological factors have been identified:
- Primary or idiopathic
- Secondary or associated with an underlying condition
- Trauma
- Systemic corticosteroid use or Cushing disease
- Alcohol abuse
- Systemic lupus erythematosus (with or without antiphospholipid syndrome), as well as other connective-tissue diseases
- Hematologic (sickle cell disease, hemoglobinopathies)
- Metabolic (hyperlipidemia, gout, renal failure)
- Orthopedic disorders (slipped capital femoral epiphysis, congenital dysplasia of the hip, Legg-Calve-Perthes disease)
- Infection (osteomyelitis, HIV infection [controversial])
- Renal transplantation
- Radiation therapy
- Pancreatitis (uncommon)
- Gaucher disease
- Malignancy (marrow infiltration, malignant fibrous histiocytoma)
- Caisson disease
- Pregnancy
- Bisphosphonate use
More on Avascular Necrosis |
Overview: Avascular Necrosis |
| Differential Diagnoses & Workup: Avascular Necrosis |
| Treatment & Medication: Avascular Necrosis |
| Follow-up: Avascular Necrosis |
| Multimedia: Avascular Necrosis |
| References |
| Further Reading |
| Next Page » |
References
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. May 16 2006;144(10):753-61. [Medline].
Kawai K, Tamaki A, Hirohata K. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head. A histochemical and electron microscopic study. J Bone Joint Surg Am. Jun 1985;67(5):755-63. [Medline].
Wang GJ, Sweet DE, Reger SI, et al. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am. Sep 1977;59(6):729-35. [Medline].
Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. Feb 2005;34(2):120-3. [Medline].
Ninomiya S. An epidemiological survey of idiopathic avascular necrosis of the femoral head in Japan. Annual Report of Japanese Investigation Committee for Intractable Disease. 1989.
Lawson-Ayayi S, Bonnet F, Bernardin E, et al. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France. Clin Infect Dis. Apr 15 2005;40(8):1188-93. [Medline].
Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop. May 2001;(386):173-8. [Medline].
Hasegawa Y, Iwata H, Torii S, et al. Vascularized pedicle bone-grafting for nontraumatic avascular necrosis of the femoral head. A 5- to 11-year follow-up. Arch Orthop Trauma Surg. 1997;116(5):251-8. [Medline].
Urbaniak JR, Coogan PG, Gunneson EB, et al. Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am. May 1995;77(5):681-94. [Medline].
Sugano N, Takaoka K, Ohzono K, et al. Rotational osteotomy for non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Br. Sep 1992;74(5):734-9. [Medline].
Agarwala S, Jain D, Joshi VR, et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). Mar 2005;44(3):352-9. [Medline].
[Guideline] Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: etiology, pathophysiology, classification, and current treatment guidelines. Am J Orthop. Jul 2004;33(7):327-32. [Medline].
Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: role of vascularized bone grafts. Orthop Clin North Am. Jan 2007;38(1):13-22, v. [Medline].
Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. May 2009;67(5 Suppl):61-70. [Medline].
Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. May 2009;67(5 Suppl):75-84. [Medline].
Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. Oct 2002;32(2):94-124. [Medline].
Bachiller FG, Caballer AP, Portal LF. Avascular necrosis of the femoral head after femoral neck fracture. Clin Orthop Relat Res. Jun 2002;87-109. [Medline].
Bernasek TL, Stahl JL, Pupello D. Pyrolytic carbon endoprosthetic replacement for osteonecrosis and femoral fracture of the hip: a pilot study. Clin Orthop Relat Res. Jul 2009;467(7):1826-32. [Medline].
Boettcher WG, Bonfiglio M, Hamilton HH, et al. Non-traumatic necrosis of the femoral head. I. Relation of altered hemostasis to etiology. J Bone Joint Surg Am. Mar 1970;52(2):312-21. [Medline].
Brunelli G, Brunelli G. Free microvascular fibular transfer for idiopathic femoral head necrosis: long-term follow-up. J Reconstr Microsurg. Oct 1991;7(4):285-95. [Medline].
Calandriello B, Grassi G. Idiopathic osteonecrosis of the femoral head. Epidemiological and aetiological factors. Ital J Orthop Traumatol. 1982;8 (Suppl):9-18.
Cruess RL. Osteonecrosis of bone. Current concepts as to etiology and pathogenesis. Clin Orthop. Jul 1986;(208):30-9. [Medline].
Delloye C, Cornu O. Cortical bone allografting in femoral head necrosis. Acta Orthop Belg. 1999;65 Suppl 1:57-61. [Medline].
Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. May 2009;67(5 Suppl):44-52. [Medline].
Dudkiewicz I, Covo A, Salai M, et al. Total hip arthroplasty after avascular necrosis of the femoral head: does etiology affect the results?. Arch Orthop Trauma Surg. Mar 2004;124(2):82-5. [Medline].
Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. Dec 1990;89(6):733-8. [Medline].
Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case-control study. Bone. Jan 1998;22(1):67-71. [Medline].
Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. May 2009;67(5 Suppl):96-106. [Medline].
Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin North Am. Apr 2009;40(2):213-21. [Medline].
Gliklich R, Wilson J. Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry. J Oral Maxillofac Surg. May 2009;67(5 Suppl):71-4. [Medline].
Goker B, Block JA. Risk of contralateral avascular necrosis (AVN) after total hip arthroplasty (THA) for non-traumatic AVN. Rheumatol Int. Jan 2006;26(3):215-9. [Medline].
Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, et al. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. AIDS Res Hum Retroviruses. Sep 2004;20(9):909-15. [Medline].
Imhof H, Breitenseher M, Trattnig S, et al. Imaging of avascular necrosis of bone. Eur Radiol. 1997;7(2):180-6. [Medline].
Ito H, Matsuno T, Kaneda K. Prognosis of early stage avascular necrosis of the femoral head. Clin Orthop Relat Res. Jan 1999;149-57. [Medline].
Jones LC, Hungerford MW, Khanuja HS, Hungerford DS. Outcome measures for evaluation of treatments for osteonecrosis. Orthop Clin North Am. Apr 2009;40(2):179-91. [Medline].
[Best Evidence] Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. Mar 2009;36(3):478-90. [Medline].
Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. Jun 2009;67(6):1167-73. [Medline].
[Best Evidence] Lai KA, Shen WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. Oct 2005;87(10):2155-9. [Medline].
Laloux P, Lefebvre S, Esselinckx W. Spinal cord compression secondary to vertebral aseptic osteonecrosis. Spine. Apr 1991;16(4):480-1. [Medline].
Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med. May 28 1992;326(22):1473-9. [Medline].
Marti-Carvajal A, Dunlop R, Agreda-Perez L. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. Oct 18 2004;CD004344. [Medline].
Milgram JW. Osteonecrosis. In: Radiologic and Histologic Pathology of Nontumorous Diseases of Bones and Joints. Northbrook Pub Co; 1990:958-1113.
Mirzai R, Chang C, Greenspan A, et al. Avascular necrosis. Compr Ther. May 1998;24(5):251-5. [Medline].
Pilmore H, Walker R, McMillan B, et al. Acute bone pain following renal transplantation: differentiation between benign bone edema and avascular necrosis. Am J Nephrol. 1998;18(1):57-60. [Medline].
Roposch A, Stöhr KK, Dobson M. The effect of the femoral head ossific nucleus in the treatment of developmental dysplasia of the hip. A meta-analysis. J Bone Joint Surg Am. Apr 2009;91(4):911-8. [Medline].
Scher MA, Jakim I. Late follow-up of femoral head avascular necrosis managed by intertrochanteric osteotomy & bone grafting. Acta Orthop Belg. 1999;65 Suppl 1:73-7. [Medline].
Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol. Jun 1997;97(4):865-70. [Medline].
Steinberg ME, Steinberg DR. The hip and its disorders. In: Steinberg ME, ed. Avascular necrosis of the femoral head. WB Saunders Co; 1991:623-47.
Suehiro M, Hirano T, Mihara K, et al. Etiologic factors in femoral head osteonecrosis in growing rats. J Orthop Sci. 2000;5(1):52-6. [Medline].
Van Laere C, Mulier M, Simon JP, et al. Core decompression for avascular necrosis of the femoral head. Acta Orthop Belg. Sep 1998;64(3):269-72. [Medline].
Wang GJ, Rawles JG, Hubbard SL, et al. Steroid-induced femoral head pressure changes and their response to lipid-clearing agents. Clin Orthop Relat Res. Apr 1983;298-302. [Medline].
Wang TY, Avlonitis EG, Relkin R. Systemic necrotizing vasculitis causing bone necrosis. Am J Med. Jun 1988;84(6):1085-6. [Medline].
Wong SY, Evans RA, Needs C, et al. The pathogenesis of osteoarthritis of the hip. Evidence for primary osteocyte death. Clin Orthop Relat Res. Jan 1987;305-12. [Medline].
Zizic TM, Marcoux C, Hungerford DS, et al. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med. Nov 1985;79(5):596-604. [Medline].
Keywords
avascular necrosis, AVN, osteonecrosis, avascular necrosis of the hip, AVN of the hip, avascular necrosis of the jaw, AVN of the jaw, corticosteroid-induced AVN, corticosteroid-induced avascular necrosis, aseptic necrosis, ischemic necrosis, femoral head necrosis, total hip arthroplasty, THA, core decompression, bone graft, bone grafting, osteotomy
Overview: Avascular Necrosis